SLEEP APNEA DIAGNOSTIC CENTER BUSINESS PLAN

I. Executive Summary

Company Description

We are a premier medical diagnostic facility in Houston, Texas, specializing in overnight sleep studies to diagnose sleep apnea. Our operation combines the clinical rigor of a hospital laboratory with the comfort of a high-end hotel to improve patient experience. We employ board-certified specialists and registered technologists to deliver clinical-grade data and patient care. One-line: launching in 2026 to serve patients who need diagnostic overnight polysomnography.

Core activities include overnight in-lab sleep studies, clinical interpretation by credentialed specialists, and patient intake and follow-up coordination. What sets us apart is the dual focus on hospital-level diagnostics and hotel-style comfort, plus independent status focused on regional leadership. Target patients are adults in the greater Houston area referred for suspected sleep apnea. Short-term goal: open in 2026 and establish referral pipelines; long-term goal: become the leading independent sleep diagnostic center and scale to $7.044 million in annual revenue within five years.

Problem

22 million Americans suffer from sleep apnea, and about 80 percent of moderate–severe cases go undiagnosed, leaving a large hidden population with untreated sleep‑disordered breathing.

Undiagnosed cases cause chronic fatigue, reduce workplace productivity, and raise risks of heart failure, stroke, and type 2 diabetes. The diagnostic market is fragmented, lacks consistent clinical oversight for complex cases, and fails to provide timely, comfortable overnight testing that could reduce downstream healthcare costs—creating a clear need for a dedicated, scalable diagnostic center.

Solution

An estimated 22 million Americans have sleep apnea and about 80 percent of moderate-to-severe cases go undiagnosed, driving higher rates of heart failure, stroke, and diabetes. Patients often avoid hospital labs and find at-home tests insufficient, creating a clear need for a diagnostic service that combines clinical accuracy with patient comfort.

Comprehensive, medically supervised overnight sleep studies delivered in private, high-end rooms using state-of-the-art polysomnography systems, overseen by board-certified specialists, and including CPAP titration and specialist follow-ups to produce a definitive diagnosis and clear treatment pathway. We deliver definitive sleep diagnoses and treatment plans in a premium clinical setting.

Mission Statement

We improve patients' quality of life by delivering timely, crucial health insights through advanced sleep diagnostics, combining clinical accuracy with patient comfort to prevent long-term complications. We serve as a trusted partner for referring physicians by providing reliable results with rapid turnaround and clear clinical guidance. We commit to setting the standard for sleep medicine in the United States and to achieving $5.122 million EBITDA by 2030.

Key Success Factors

These are the critical drivers that will make the Sleep Apnea Diagnostic Center viable and investable.

• Dedicated Physician Liaison—maintains and grows strong referring-physician relationships.
• Rapid turnaround—fast referral-to-results time provides a competitive edge in Houston.
• AASM accreditation and board-certified specialists—ensures high clinical standards and trust.
• Operational efficiency—target 85% technical-staff capacity utilization to control costs.
• Attractive financials—13.06% IRR and a 15-month payback period.

Financial Summary

Below is a concise financial snapshot for the Executive Summary.

The project requires a minimum cash reserve of $680,000, targets breakeven in Jan-26, offers an internal rate of return of 13.06% and a return on equity of 13.89%, and achieves capital payback in 15 months.

Financial outlook: revenue and EBITDA scale rapidly to strong positive cash flow and investor returns by year three.

Funding Requirements

The project requires $1,132,000 to purchase equipment, complete the facility, and fund operations until revenue stabilizes.

Year-one revenue is projected at $1,290,000, growing to $7,044,000 by year five; EBITDA rises from $445,000 to $5,122,000, breakeven occurs January 2026 (first month), return on equity is 13.89%, IRR is 13.06%, and payback is 15 months.